LuciEncor (Encorafenib) 75mg Capsules | BRAF Inhibitor | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: LuciEncor (Laos)
LuciEncor is a Laos-manufactured generic brand of encorafenib produced by Lucius Pharmaceuticals (Lao) Co., Ltd. It is supplied as 75 mg capsules in a 90-capsule box. Encorafenib is a selective BRAF kinase inhibitor that targets the BRAF V600E and V600K mutations found in a subset of melanomas, colorectal cancers and non-small cell lung cancers. LuciEncor provides the same encorafenib active ingredient as the originator, offering a lower-cost option for sustained BRAF-targeted treatment.
What Is LuciEncor (Encorafenib) Used For?
LuciEncor is used for adults whose tumours carry a BRAF V600 mutation. Encorafenib is prescribed, in specific combinations, for BRAF V600-mutant melanoma, BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant metastatic non-small cell lung cancer. Because the drug acts only on mutant BRAF, a genomic test confirming the mutation is mandatory before treatment begins.
How Does Encorafenib Work?
Encorafenib binds to and inhibits the mutant BRAF V600 kinase, interrupting the hyperactive MAPK signalling pathway that drives BRAF-mutant tumour growth. Blocking this signal slows cancer-cell proliferation and promotes cell death while leaving normal cells largely unaffected. Combining encorafenib with a MEK inhibitor such as binimetinib or with cetuximab blocks the pathway at two levels, improving response and delaying the development of resistance.
Indications
Encorafenib is indicated for BRAF-mutant cancers in defined combinations: with binimetinib for unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation, with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer, and with cetuximab for BRAF V600E-mutant metastatic colorectal cancer after prior systemic therapy. It is not indicated for BRAF wild-type tumours and requires oncologist supervision.
Dosage
The recommended dose of encorafenib depends on the indication: 450 mg (six 75 mg capsules) once daily for melanoma and lung cancer, and 300 mg (four 75 mg capsules) once daily for colorectal cancer, each with the prescribed partner drug. The 90-capsule box of LuciEncor covers about two weeks of treatment at the 300 mg dose. The prescribing oncologist may adjust the dose or schedule based on tolerance and side effects, and patients should follow the plan exactly.
Side Effects
The most common side effects of encorafenib are fatigue, nausea, vomiting, diarrhoea, abdominal pain and reduced appetite. Skin reactions — rash, itching and new skin lesions — are frequent and warrant dermatological review. Fever, joint or muscle pain, headache and changes in liver enzymes or blood counts may also occur. New or changing skin growths, eye problems or unusual bleeding should be reported to the treating doctor promptly.
Storage
Store LuciEncor capsules at room temperature, away from moisture and heat, in their original packaging. Keep out of the reach of children and do not use after the expiry date. Refrigeration is not required.
Why Choose the GLT?
LuciEncor offers the same encorafenib active ingredient as the originator at a more affordable price, an important advantage for patients facing extended courses of BRAF-targeted therapy. Through GLT, institutions and individual patients gain a verified, traceable route to this Laos-manufactured generic, with authenticity checks, current availability and complete export documentation handled end to end.
How to Order
To source LuciEncor (encorafenib) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity and your destination country, and we will confirm current stock, sourcing origin and the import documentation required. A valid prescription and BRAF-mutation test result are required, and we serve both institutions and individual patients.
FAQ
Is LuciEncor the same as Braftovi? LuciEncor is a generic brand of encorafenib, the same active ingredient as the originator Braftovi, manufactured by Lucius Pharmaceuticals in Laos.
Which cancers does encorafenib treat? Encorafenib is used for BRAF V600-mutant melanoma, BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant metastatic non-small cell lung cancer in specific combinations.
Do I need a BRAF test before using LuciEncor? Yes. A confirmed BRAF V600E or V600K mutation is required, as encorafenib does not act on BRAF wild-type tumours.
What pack size is LuciEncor available in? LuciEncor is supplied as 75 mg capsules in a 90-capsule box, covering 15 days of standard dosing.
Is a prescription required? Yes. Encorafenib is a prescription oncology medicine and must be used under an oncologist's supervision.